布雷维亚胺 F 通过调节 MAPK 信号通路和凝结级联,产生抗血栓作用
Huiwen Zhang1,2, Chen Sun1,2, Qing Xia1,2
1Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China.
布雷维亚纳米德F是一种天然产品,通过减少血小板聚合,有效地减少斑马鱼的血栓. 这种深海化合物显示出开发更安全的抗血栓治疗方法的前景.
科学领域:
- 药理学 药理学是指药理学的学科.
- 海洋天然产品 海洋天然产品
- 血栓形成研究研究
背景情况:
- 目前的抗血栓药物具有显著的出血风险,需要新型治疗药物,其安全性和有效性配置有所改善.
- 血栓形成异常的特征是血栓形成异常,仍然是全球心血管疾病和死亡的主要原因.
研究的目的:
- 研究来自深海生物的化合物Brevianamide F的抗血栓潜力和潜在机制.
- 在斑马鱼血栓形成模型中评估Brevianamide F的疗效,评估其对血小板聚合和血流的影响.
主要方法:
- 利用斑马鱼血栓形成模型来评估抗血栓活性.
- 采用转录组测序和RT-qPCR进行机械洞察.
- 进行分子对接以验证路径相互作用.
主要成果:
- 布雷维亚纳米德F显著减少斑马鱼的血小板聚合和血栓形成.
- 观察到循环血小板数量增加,血液返回心脏的改善,心率升高,血液流动速度恢复.
- 转录组分析表明MAPK信号通路和凝血级联的调制.
结论:
- 布雷维亚纳米德F显示出强大的抗血栓作用,具有潜在的良好的安全性.
- 该化合物的机制涉及调节MAPK通路和凝固过程.
- 布雷维亚胺 F 是开发新型抗血栓性药物的有希望的候选药物.
更多相关视频
07:13Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
